May Han
Private Equity Investor bei Cure Ventures Management LP
Profil
May Han is currently a Partner at Cure Ventures Management LP since 2021.
Prior to this, she worked as a Director at Novartis AG from 2013 to 2021 and as a Director at AVEO Pharmaceuticals, Inc. from 2003 to 2012.
Dr. Han received her undergraduate degree from Peking University in 1990 and her doctorate degree from Yale University in 1996.
Aktive Positionen von May Han
Unternehmen | Position | Beginn |
---|---|---|
Cure Ventures Management LP
Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01.09.2021 |
Ehemalige bekannte Positionen von May Han
Unternehmen | Position | Ende |
---|---|---|
NOVARTIS AG | Direktor/Vorstandsmitglied | 30.09.2021 |
AVEO PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 30.06.2012 |
Ausbildung von May Han
Peking University | Undergraduate Degree |
Yale University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
NOVARTIS AG | Health Technology |
Private Unternehmen | 2 |
---|---|
Cure Ventures Management LP
Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Finance |
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |